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MaOBJECTIVES The purpose of this study was to compare the long-term clinical outcomes of patients with chronic total
occlusion (CTO) and well-developed collateral circulation treated with revascularization versus medical therapy.
BACKGROUND Little is known about the clinical outcomes and optimal treatment strategies of CTO with well-
developed collateral circulation.
METHODS We screened 2,024 consecutive patients with at least 1 CTO detected on coronary angiogram. Of these, we
analyzed data from 738 patients with Rentrop 3 grade collateral circulation who were treated with medical therapy alone
(n ¼ 236), coronary artery bypass grafting (n ¼ 170) or percutaneous coronary intervention (n ¼ 332; 80.1% successful).
Patients who underwent revascularization and medical therapy (revascularization group, n ¼ 502) were compared with
those who underwent medical therapy alone (medication group, n ¼ 236) in terms of cardiac death and major adverse
cardiac events (MACE), deﬁned as the composite of cardiac death, myocardial infarction, and repeat revascularization.
RESULTS During a median follow-up duration of 42 months, multivariate analysis revealed a signiﬁcantly lower inci-
dence of cardiac death (hazard ratio [HR]: 0.29; 95% conﬁdence interval [CI]: 0.15 to 0.58; p < 0.01) and MACE (HR:
0.32; 95% CI: 0.21 to 0.49; p < 0.01) in the revascularization group compared with the medication group. After pro-
pensity score matching, the incidence of cardiac death (HR: 0.27; 95% CI: 0.09 to 0.80; p ¼ 0.02) and MACE (HR: 0.44;
95% CI: 0.23 to 0.82; p ¼ 0.01) were still signiﬁcantly lower in the revascularization group than in the medication group.
CONCLUSIONS In patients with coronary CTO and well-developed collateral circulation, aggressive revascularization
may reduce the risk of cardiac mortality and MACE. (J Am Coll Cardiol Intv 2015;8:271–9) © 2015 by the American
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ABBR EV I A T I ON S
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MACE = major adverse cardiac
events
MI = myocardial infarction
PCI = percutaneous coronary
intervention
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272patients with CTO has also increased due to
improvements in device technology such as
drug-eluting stents, dedicated guidewires,
and microcatheters (5,6). However, high fre-
quencies of failed PCI, perioperative mortal-
ity, and potential lethal complications
related to revascularization still exist in pa-
tients with CTO (5). For these reasons, some
clinicians are more likely to treat patients
who have CTO and abundant distal collateral
ﬂow with medical therapy alone. To date, nostudies have compared the long-term clinical out-
comes of patients with CTO andwell-developed collat-
eral circulation who undergo medical therapy versus
those who undergo revascularization. Therefore,
this study aimed to compare the long-term survival
outcomes associated with revascularization versus
medical therapy in patients with at least 1 CTO and
well-developed collateral circulation.SEE PAGE 280METHODS
STUDY POPULATION. Between March 2003 and
February 2012, 2,024 consecutive patients were
enrolled in the retrospective Samsung Medical Center
CTO registry. The inclusion criteria for the registry
were: 1) at least 1 CTO detected on diagnostic coro-
nary angiography; and 2) symptomatic angina and/or
a positive functional ischemia study. Exclusion
criteria included: 1) previous CABG; 2) history of
cardiogenic shock or cardiopulmonary resuscitation;
and 3) ST-segment elevation acute myocardial
infarction (MI) during the preceding 48 h. A CTO
lesion was deﬁned as the obstruction of a native
coronary artery with a Thrombolysis In Myocardial
Infarction (TIMI) ﬂow grade 0 with an estimated
duration longer than 3 months. Duration was esti-
mated based on the interval from the last episode of
acute coronary syndrome (ACS), or in patients with no
history of ACS, from the ﬁrst episode of exertional
angina consistent with the location of the occlusion
or previous coronary angiogram (7–9).
Of the 2,024 patients included in the registry, 738
patients had Rentrop grade 3 collateral ﬂow (10) and
were included in the ﬁnal analysis. The institutional
review board of Samsung Medical Center approved
this study and waived the requirement for informed
consent.
WELL-DEVELOPED COLLATERAL CIRCULATION.
Coronary angiography was reviewed by experienced
interventional cardiologists blinded to patient data,and the extent of collateral ﬂow was assessed ac-
cording to the validated Rentrop classiﬁcation scale
(10). The grades of collateral ﬁlling from the contra-
lateral vessel were: 0 ¼ none; 1 ¼ ﬁlling of side
branches of the artery to be dilated via collateral
channels without visualization of the epicardial
segment; 2 ¼ partial ﬁlling of the epicardial segment
via collateral channels; and 3 ¼ complete ﬁlling of the
epicardial segment of the artery to be dilated via
collateral channels. We considered patients with
well-developed collateral circulation to have Rentrop
grade 3 collateral ﬂow. After selection of these pa-
tients, we conﬁrmed the Rentrop grades by reviewing
the associated angiograms in all cases.
TREATMENT STRATEGY. All patients received anti-
platelet therapy with aspirin at a dose of 81 to 325 mg/
day, or clopidogrel at 75 mg/day if aspirin intolerance
was reported. All patients were taking 1 or more
antianginal medications, including a long-acting
beta-blocker, calcium-channel blocker, and iso-
sorbide mononitrate, alone or in combination, along
with either an angiotensin-converting enzyme in-
hibitor or an angiotensin receptor blocker as standard
secondary prevention. All patients received a high-
dose statin alone or in combination with ezetimibe
in order to reduce the low-density lipoprotein
cholesterol level to a target level of 60 to 85 mg/dl
(1.55 to 2.20 mmol/l). The dosages of all medications
were maximized as allowed by heart rate, blood
pressure, and side effects in the absence of justiﬁable
relative contraindications.
Revascularization of CTOs was accomplished by
CABG or PCI with drug-eluting stent, and each
revascularization strategy was selected as a treatment
option based on the patient’s and physician’s pref-
erence. In a case of CABG for CTOs, arterial grafting
with off-pump coronary artery bypass was the
preferred technique. The surgical risk was assessed
using the EuroSCORE (mean  SD), and high surgical
risk was deﬁned as a EuroSCORE of $6 (11). PCI was
performed using contemporary techniques such as
bilateral injections; a specialized stiff, hydrophilic
wire with a tapered tip; microcatheters; and a retro-
grade approach when available. The decision to
pursue invasive treatment, the access site, type of
drug-eluting stent, use of intravascular ultrasound,
and use of glycoprotein IIb/IIIa receptor inhibitor
were all left to the operator’s discretion. All in-
terventions and procedural anticoagulation were
performed according to current standard guidelines.
All patients received loading doses of aspirin (300 mg)
and clopidogrel (300 to 600 mg) before PCI unless
they had previously received these antiplatelet
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273medications. Aspirin treatment was continued
indeﬁnitely, and the duration of clopidogrel treat-
ment was also left to the discretion of the individual
physician. Successful revascularization was deﬁned
as ﬁnal residual stenosis <20% of the vessel diameter,
with TIMI ﬂow grade $2 after revascularization, as
assessed by visual estimation of the angiograms (7).
DATA COLLECTION. Clinical, angiographic, proce-
dural, and outcome data were collected using a web-
based reporting system. Additional information was
obtained by reviewing the medical records or by
telephone contact, if necessary. All baseline and
procedural cine coronary angiograms were reviewed
and analyzed quantitatively at the angiographic core
laboratory (Cardiac and Vascular Center, Samsung
Medical Center, Seoul, Korea) with an automated
edge-detection system (Centricity CA 1000, GE,
Waukesha, Wisconsin) using standard deﬁnitions
(12). The minimum luminal diameters (MLDs) were
measured in matched views before and after main
vessel stenting if applicable. For the main vessel, the
reference diameter (RD) was the average of the
proximal and distal reference lumen diameters. For
the side branch, the RD was the distal reference
lumen diameter. Diameter stenosis was calculated as:
100  (RD  MLD)/RD.
STUDY OUTCOMES AND DEFINITIONS. The primary
outcome was cardiac death during follow-up. The
secondary outcomes were all-cause death, MI, repeat
revascularization, and major adverse cardiac event
(MACE). Repeat revascularization was a composite of
target vessel revascularization (TVR) and non-TVR
treated with PCI or CABG. MACE was deﬁned as a
composite of cardiac death, MI, and repeat revascu-
larization. All deaths were considered to be of cardiac
origin unless a deﬁnite noncardiac cause could be
established. MI was deﬁned as an elevation of crea-
tine kinase-MB fraction or troponin-T/troponin-I
greater than the upper limit of normal with concom-
itant ischemic symptoms or electrocardiographic
ﬁndings indicative of ischemia (13). Perioperative
enzyme elevation was not included in this deﬁnition
of MI. TVR indicates the repeated revascularization of
the target vessel by PCI or CABG; non-TVR indicates
repeated revascularization of any vessel other that
the target vessel by PCI or CABG.
STATISTICAL ANALYSIS. All statistical analyses were
performed using the intent-to-treat principle.
Continuous variables were compared using the Stu-
dent t test or the Wilcoxon rank-sum test where
applicable and were presented as mean  SD or me-
dian with interquartile range. Categorical data weretested using the Fisher exact test or the chi-square
test as appropriate. Cumulative event rates were
estimated by the Kaplan-Meier method, and treat-
ment effects were assessed using stratiﬁed log-rank
statistics. Covariates that were either statistically
signiﬁcant on univariate analysis or clinically rele-
vant were included in multivariate models. Adjusted
hazard rates were compared by Cox regression based
on age, history of ACS, CTO of the left anterior
descending coronary artery, multiple CTOs, previous
PCI, and proximal to mid CTO. To reduce selection
bias for treatment and any other related potential
confounding factor, we performed a baseline charac-
teristic adjustment for patients using propensity
scores. Propensity scores were estimated using mul-
tiple logistic regression analysis. A full non-
parsimonious model was developed that included all
variables listed in Tables 1 and 2. The discrimination
and calibration abilities of this propensity score
model were assessed using c-statistics. Pairs were
matched 1:1 by an optimal balance based on a genetic
algorithm. We assessed the balance in baseline
covariates between the 2 groups in a propensity
score-matched cohort through the standardized mean
difference and hypothesis test using the stratiﬁed
analyses considering matched pairs (2-way analysis of
variance or Friedman test) for continuous variables
and the Mantel-Haenszel method for categorical var-
iables. In the propensity score-matched population,
risk reductions were compared using a conditional
Cox regression model (14). All tests were 2-tailed, and
p < 0.05 was considered to be statistically signiﬁcant.
All analyses were performed with the Statistical
Analysis Software package, version 9.2, (SAS Insti-
tute, Cary, North Carolina).
RESULTS
PATIENT CHARACTERISTICS. Of the 2,024 patients
in the registry, 738 patients had at least 1 CTO and
well-developed collateral circulation, of whom 236
patients were treated with medical therapy alone
(32%, medication group) and 502 patients were
treated with PCI or CABG (68%, revascularization
group). Of the 502 patients who underwent revascu-
larization, 170 patients underwent CABG and 332 pa-
tients underwent PCI. Of the 332 patients who
underwent PCI, 266 patients (80.1%) were successfully
revascularized. The extent of coronary disease did not
vary between the 2 groups (2.2  0.8 in the revascu-
larization group vs. 2.1  0.7 in the medication group,
p ¼ 0.73), but the number of treated vessels was
signiﬁcantly greater in the revascularization group
than in the medication group (1.5  1.0 vs. 0.5  0.7,
TABLE 1 Baseline Clinical Characteristics
Total Population (n ¼ 738) Propensity-Matched Population (n ¼ 430)
Medication
(n ¼ 236)
Revascularization
(n ¼ 502) p Value
Standardized
Difference
Medication
(n ¼ 215)
Revascularization
(n ¼ 215) p Value
Standardized
Difference
Age (yrs) 65.6  12.0 61.6  10.2 <0.01 38.9 65.3  12.1 64.5  9.5 0.42 7.4
Male 190 (80.5) 419 (83.5) 0.32 8.0 172 (80.0) 176 (81.9) 0.64 5.0
Diabetes mellitus 109 (46.2) 237 (47.2) 0.80 2.1 103 (47.9) 101 (47.0) 0.85 1.9
Hypertension 155 (65.7) 320 (63.7) 0.61 4.0 140 (65.1) 137 (63.7) 0.77 2.9
Dyslipidemia 54 (22.9) 179 (35.7) <0.01 26.6 52 (24.2) 53 (24.7) 0.91 1.0
Current smoker 63 (27.1) 153 (30.5) 0.35 7.3 58 (27.0) 63 (29.3) 0.60 5.0
Chronic renal failure 29 (12.3) 40 (8.0) 0.06 15.9 25 (11.6) 24 (11.2) 0.88 1.7
ACS 33 (14.0) 104 (20.7) 0.03 16.6 32 (14.9) 32 (14.9) >0.99 0.0
Previous CVA 19 (8.1) 40 (8.0) 0.97 3.0 16 (7.4) 16 (7.4) >0.99 0.0
Previous PCI 66 (28.0) 83 (16.5) <0.01 30.7 55 (25.6) 51 (23.7) 0.64 5.0
LVEF (%) 54.7  13.0 56.9  12.6 0.04 16.1 55.3  12.4 55.7  12.5 0.74 3.2
Values are mean  SD or n (%).
ACS ¼ acute coronary syndrome; CVA ¼ cerebrovascular accident; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary
intervention.
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274p < 0.01). The EuroSCORE of patients treated with
medical therapy, PCI, or CABG was 4.9  3.6, 3.6  2.9,
or 4.5  3.3, respectively. Baseline characteristics of
the 2 groups are shown in Table 1. Compared with the
medication group, the revascularization group was
younger and had signiﬁcantly lower prevalence of
previous PCI but higher prevalence of dyslipidemia
and ACS. The left ventricular ejection fraction was
higher in the revascularization group. Angiographic
analysis showed that CTO of the left anterior
descending coronary artery, multiple CTOs, and
proximal to mid CTO were noted more frequently in
the revascularization group. The SYNTAX score (15)
was higher in the revascularization group (Table 2).TABLE 2 Angiographic Characteristics
Total Population (n ¼ 738)
Medication
(n ¼ 236)
Revascularization
(n ¼ 502) p Value
Sta
Di
Multivessel disease 186 (78.8) 390 (77.7) 0.73
CTO location
RCA 122 (51.7) 235 (46.8) 0.22
LM 0 (0) 0 (0)
LAD 64 (27.1) 204 (40.6) <0.01
LCx 78 (33.1) 170 (33.9) 0.83
Multiple CTOs 26 (11.0) 99 (19.7) <0.01
Abrupt stump 118 (52.4) 222 (45.2) 0.08
Bridge collaterals 96 (42.3) 191 (39.4) 0.46
Calciﬁcation 51 (21.6) 95 (18.9) 0.39
Proximal to mid CTO* 143 (60.6) 363 (72.3) <0.01
SYNTAX score 19.9  10.0 23.0  11.0 <0.01
Values are n (%) or mean  SD. *“CTO of the proximal to middle portions of the vessel
CTO ¼ coronary chronic total occlusion; LAD ¼ left anterior descending artery; LCx ¼Complicated revascularization occurred in 26 patients
(5.2% of the revascularization group). There were no
deaths associated with the revascularization therapy,
but cerebrovascular accidents including stroke
occurred in 18 patients (3.6%), cardiac tamponade in 4
patients (0.8%), and cardiogenic shock in 2 patients
(0.4%). Periprocedural MI (16) occurred in 70 patients
(15.0%) in the revascularization group. A total of 35
patients (20.6%) treated with CABG and 35 patients
(11.7%) treated with PCI suffered from this periproce-
dural complication.
CLINICAL OUTCOMES. Complete follow-up data
were obtained in the overall study population. During
follow-up (median 42 months, interquartile range: 22Propensity-Matched Population (n ¼ 430)
ndardized
fference
Medication
(n ¼ 215)
Revascularization
(n ¼ 215) p Value
Standardized
Difference
3.8 167 (77.7) 160 (74.4) 0.43 7.6
9.8 110 (51.2) 109 (50.7) 0.92 0.9
0 (0) 0 (0)
27.5 61 (28.4) 67 (31.2) 0.49 5.7
1.7 72 (33.5) 66 (30.7) 0.55 5.9
21.9 26 (12.1) 26 (12.1) >0.99 0.0
11.6 108 (50.2) 113 (52.6) 0.60 4.7
5.4 88 (40.9) 88 (40.9) >0.99 0.0
6.9 47 (21.9) 46 (21.4) 0.91 1.2
26.2 131 (60.9) 138 (64.2) 0.84 7.3
27.5 20.3  10.0 20.8  10.9 0.60 4.4
” has been abbreviated as “Proximal to mid CTO.”
left circumﬂex artery; LM ¼ left main coronary artery; RCA ¼ right coronary artery.
TABLE 3 Clinical Outcomes in All Study Patients (n ¼ 738)
Medication
(n ¼ 236)
Revascularization
(n ¼ 502)
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI)* p Value
All-cause death 44 (18.6) 39 (7.8) 0.39 (0.26–0.61) <0.01 0.44 (0.27–0.71) <0.01
Cardiac death 23 (9.7) 17 (3.4) 0.33 (0.18–0.61) <0.01 0.29 (0.15–0.58) <0.01
MI 2 (0.8) 4 (0.8) 0.91 (0.17–4.98) 0.92 1.04 (0.16–6.80) 0.97
Repeat revascularization† 37 (15.7) 34 (6.8) 0.38 (0.24–0.61) <0.01 0.38 (0.23–0.63) <0.01
MACE‡ 59 (25.0) 51 (10.2) 0.36 (0.25–0.52) <0.01 0.32 (0.21–0.49) <0.01
Values are n (%). *Adjusted covariates include age, ACS, CTO of LAD, multiple CTOs, previous PCI, and proximal to mid CTO. †Repeat revascularization included target vessel
revascularization-PCI, non–target vessel revascularization-PCI, and coronary artery bypass grafting (CABG). ‡Major adverse cardiac events (MACE) included cardiac death, MI,
and repeat revascularization with PCI or CABG.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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275to 68 months), 40 cardiac deaths occurred (23 in the
medication group [9.7%] vs. 17 in the revasculariza-
tion group [3.4%], p < 0.01). In multivariate analysis,
the revascularization group was found to have
signiﬁcantly lower risk of cardiac death (hazard ratio
[HR]: 0.29; 95% conﬁdence interval [CI]: 0.15 to 0.58;
p < 0.01), all-cause death (HR: 0.44; 95% CI: 0.27 to
0.71; p < 0.01), repeat revascularization (HR: 0.38;
95% CI: 0.23 to 0.63; p < 0.01), and MACE (HR: 0.32;
95% CI: 0.21 to 0.49; p < 0.01). The incidence of MI
(HR: 1.04; 95% CI: 0.16 to 6.80; p ¼ 0.97) were similar
between 2 groups (Table 3, Figures 1A and 1B).
PROPENSITY SCORE-MATCHED ANALYSIS. After per-
forming propensity score matching, a total of 215
pairs were generated. The c-statistic for the pro-
pensity score model was 0.75, indicating good
discrimination. There were no signiﬁcant differences
in baseline clinical or angiographic characteristics for
the propensity score-matched subjects (Tables 1
and 2). A total of 29 cardiac deaths occurred duringFIGURE 1 Kaplan-Meier Curves for Clinical Outcomes in the Overall
(A) Kaplan-Meier curves for cardiac death in the patients treated with cor
versus medical therapy alone (medication group). (B) Kaplan-Meier curvfollow-up in the matched patients. Compared with
the medication group, the revascularization group
had a lower prevalence of cardiac death (20 in the
medication group [9.3%] vs. 9 in the revascularization
group [4.2%], HR: 0.27; 95% CI: 0.09 to 0.80; p ¼
0.02), all-cause death (18.1% vs. 7.4%, HR: 0.23; 95%
CI: 0.10 to 0.53; p < 0.01) and MACE (24.7% vs. 10.7%,
HR: 0.44; 95% CI: 0.23 to 0.82; p ¼ 0.01). However,
there were no signiﬁcant differences in incidence of
MI (0.5% vs. 0.9%, HR: 2.00; 95% CI: 0.18 to 22.06; p ¼
0.57) or repeat revascularization (15.3% vs. 6.5%, HR:
0.59; 95% CI: 0.27 to 1.29; p ¼ 0.18) between the 2
groups (Table 4, Figures 2A and 2B).
SUBGROUP ANALYSIS OF THE REVASCULARIZATION
GROUP. The revascularization group was composed
of the CABG subgroup (n ¼ 170, 34% of the re-
vascularization group) and the PCI subgroup (n ¼
332, 66%); there were no signiﬁcant differences in
clinical outcomes between the 2 subgroups with the
exception of MACE, which was primarily driven byPopulation
onary revascularization and medical therapy (revascularization group)
es for major adverse cardiac events (MACE).
TABLE 4 Clinical Outcomes in Propensity-Matched Patients (n ¼ 430)
Medication
(n ¼ 215)
Revascularization
(n ¼ 215) HR (95% CI) p Value
All-cause death 39 (18.1) 16 (7.4) 0.23 (0.10–0.53) <0.01
Cardiac death 20 (9.3) 9 (4.2) 0.27 (0.09–0.80) 0.02
MI 1 (0.5) 2 (0.9) 2.00 (0.18–22.06) 0.57
Repeat revascularization* 33 (15.3) 14 (6.5) 0.59 (0.27–1.29) 0.18
MACE† 53 (24.7) 23 (10.7) 0.44 (0.23–0.82) 0.01
Values are n (%). *Repeat revascularization included target vessel revascularization-PCI, non–target vessel
revascularization-PCI, and CABG. †Major adverse cardiac events (MACE) included cardiac death, MI, and repeat
revascularization with PCI or CABG.
Abbreviations as in Tables 1 and 3.
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276repeat revascularization. In multivariate analysis
adjusted for diabetes mellitus, the left ventricular
ejection fraction (%), and SYNTAX score, the PCI
subgroup had a signiﬁcantly higher prevalence of
repeat revascularization (HR: 7.30; 95% CI: 2.09 to
25.46; p < 0.01) and MACE (HR: 2.23; 95% CI: 1.11 to
4.49; p ¼ 0.03) compared with the CABG subgroup.
However, the incidence of cardiac death (HR: 0.54;
95% CI: 0.19 to 1.56; p ¼ 0.25), all-cause death (HR:
1.05; 95% CI: 0.51 to 2.14; p ¼ 0.90) and MI (HR: 3.83;
95% CI: 0.31 to 47.02; p ¼ 0.29) were not signiﬁcantly
different between the 2 subgroups (Table 5).
SUBGROUP ANALYSIS OF THE FAILED CTO-PCI
GROUP. Of 66 patients with failed CTO-PCI, 33 pa-
tients (50% of patients with failed CTO-PCI) were
treated with medical therapy, 9 patients (13.6%) with
CABG, and 24 patients (36.4%) with a reattempt at
PCI. A total of 6 failed CTO-PCI patients (25% of the
reattempted CTO-PCI patients) were successfully
treated with reattempt PCI. Among 9 failed CTO-PCIFIGURE 2 Kaplan-Meier Curves for Clinical Outcomes in Propensity-
(A) Kaplan-Meier curves for cardiac death. (B) Kaplan-Meier curves forpatients treated with CABG, 4 patients emergently
underwent CABG because of hypotension or sus-
tained chest pain, and 5 patients electively under-
went CABG several weeks later (Figure 3). In the failed
CTO-PCI patients, 4 all-cause deaths (6.1% of failed
CTO-PCI patients), 2 cardiac deaths (3.0%), and no
MIs occurred during follow-up duration.
DISCUSSION
We investigated the long-term clinical outcomes of
coronary revascularization versus medical therapy in
patients with CTO and well-developed collateral cir-
culation using a large dedicated registry. The primary
ﬁnding of our study was that patients with CTO and
well-developed collateral circulation who underwent
revascularization had signiﬁcantly lower risk of car-
diac death, all-cause death, and MACE compared with
those treated with medical therapy alone. Although
this study was limited by its observational design,
this is the ﬁrst report speciﬁcally addressing the issue
of revascularization and collateral circulation, and it
evaluated the potential survival beneﬁt related with
the revascularization in those CTO patients.
Several studies have shown a survival beneﬁt in
patients with CTO who undergo successful PCI
compared with those who undergo failed procedures,
suggesting that survival depends on procedural suc-
cess (17,18). However, these results are limited in their
application, as it is difﬁcult to predict the success of an
intervention. In contrast to previous studies, we
evaluated the clinical outcomes of overall treatment
strategies (including medical therapy, CABG, success-
ful PCI, or failed PCI, and so on) using an intent-to-treat
analysis of a large, dedicated registry. Therefore, ourMatched Patients
major adverse cardiac events (MACE).
TABLE 5 Clinical Outcomes of Revascularization Subgroups (Total Population n ¼ 502)
CABG (n ¼ 170) PCI (n ¼ 332) Unadjusted HR (95% CI) p Value Adjusted HR (95% CI)* p Value
All-cause death 19 (11.2) 20 (6.0) 0.58 (0.31–1.08) 0.09 1.05 (0.51–2.14) 0.90
Cardiac death 10 (5.9) 7 (2.1) 0.39 (0.15–1.04) 0.06 0.54 (0.19–1.56) 0.25
MI 1 (0.6) 3 (0.9) 1.53 (0.16–14.71) 0.71 3.83 (0.31–47.02) 0.29
Repeat revascularization† 3 (1.8) 31 (9.3) 6.11 (1.86–20.01) <0.01 7.30 (2.09–25.46) <0.01
MACE‡ 13 (7.6) 38 (11.4) 1.72 (0.92–3.24) 0.09 2.23 (1.11–4.49) 0.03
Values are n (%). *Adjusted covariates include DM, LVEF (%), and SYNTAX score. †Repeat revascularization included target vessel revascularization-PCI, non–target vessel
revascularization-PCI, and coronary artery bypass grafting (CABG). ‡Major adverse cardiac events (MACE) included cardiac death, MI, and repeat revascularization with PCI
or CABG.
DM ¼ diabetes mellitus; other abbreviations as in Tables 1 and 3.
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277results would be helpful when making a clinical deci-
sion in real-world practice.
PERSISTENT MYOCARDIAL ISCHEMIA DESPITE
ABUNDANTCOLLATERALCIRCULATION. Distal coronary
collateral is frequently present in patients with CTO,
with a catheterization-documented incidence of 80%
to 90% (19). Hansen (20) reported that distal collat-
eralization led to greatly improved survival and
freedom from MI in patients with ischemic heartFIGURE 3 Flow Chart
Flow chart of patients with failed chronic total occlusion (CTO)–percutadisease. Theoretically, well-developed collateral cir-
culation may also improve survival and be a protector
in patients with CTO. On the basis of this theoretical
protective effect of distal collateral circulation in pa-
tients with ischemic heart disease, many clinicians
recommend medical therapy alone in order to avoid
procedural complications. However, this clinical de-
cision is based on data generated from patients with
stable nonocclusive coronary disease rather than on
patients with CTO. Moreover, several publishedneous coronary intervention (PCI) during follow-up duration.
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278studies have reported a weak relationship between
visualized collaterals and cardiac events (21,22). In
addition, it has been reported that coronary steal, the
phenomenon of decreased collateral ﬂow due to
microvascular dilation, causes poor myocardial oxy-
gen supply through the collaterals and can gradually
damage the myocardium (23). Therefore, even well-
developed collateral circulation may not protect the
myocardium. In our study, patients with CTO and
abundant collateral circulation who underwent
revascularization had signiﬁcantly better outcomes
compared with those treated with medical therapy
alone. In line with previous studies, our ﬁndings
suggest that the recovery of anterograde coronary
artery ﬂow, even in patients with CTO and abundant
collateral circulation, may reduce myocardial
ischemia and, thus, adverse cardiac events.
PROTECTION OF VIABLE MYOCARDIUM BY COLLATERAL
FLOW. Previous experimental and clinical data
suggest that collateral blood ﬂow protects the
myocardium in patients with CTO. For example, our
group reported that the transmural extent of
myocardial injury and the presence of regional left
ventricular dysfunction were inversely related to the
degree of collaterals as determined by angiography
(24). Similarly, Steg et al. (25) reported that well-
developed collaterals may reduce transmural
myocardial ischemia and allow the tissue to maintain
a more viable myocardium if anterograde ﬂow is
severely reduced or absent. If abundant collateral
ﬂow maintains the viability of a larger amount of
myocardial tissue, revascularization may allow for
complete recovery of this myocardium and improve
overall heart function, reduce ventricular remodel-
ing, and prevent fatal arrhythmia (26,27).
POTENTIAL BENEFITS OF LATE PATENCY OF THE
INFARCT-RELATED ARTERY. Kim and Braunwald
(28) suggested that late myocardial reperfusion con-
fers several beneﬁts, including recovered left ven-
tricular function and improved survival resulting
from myocardial salvage, which has given rise to what
has been called the “open-artery hypothesis.” Erne
et al. (29) also reported that, among patients with
silent ischemia after MI, PCI compared with anti-
ischemic drug therapy reduced the long-term risk of
major cardiac events. They reported that openinfarct-related artery conferred improved healing of
infarcted tissue, prevention of infarct expansion, and
prevention of ventricular remodeling.
STUDY LIMITATIONS. First, the design of this study
was nonrandomized, retrospective, and observa-
tional, which may have signiﬁcantly affected the re-
sults due to confounding factors. Second, because of
the retrospective nature of our registry, we could not
thoroughly identify the alteration of medical therapy
in all study patients during follow-up duration. Third,
the Rentrop classiﬁcation of coronary collateral cir-
culation only reﬂects collaterals visualized by angi-
ography and may not reﬂect their functional
capabilities or physiologic consequences. Fourth, our
study population had a high prevalence of multi-
vessel disease, and our results may not be generaliz-
able to populations with less severe disease. Fifth, we
did not routinely evaluate the amount of viable
myocardium or ischemia of study patients using
functional ischemia testing. Finally, the high rates of
complete arterial graft and off-pump surgery or suc-
cessful PCI seen in our hospital and the low rates of
MI may have been affected by racial differences or
underestimation, and this may limit the generaliz-
ability of our results.CONCLUSIONS
In patients with CTO and well-developed collateral
circulation, revascularization coupled with medical
therapy signiﬁcantly decreased the long-term risk of
cardiac death, all-cause death, and MACE compared
with treatment with medical therapy alone. Based
on our results, revascularization may be recom-
mended as an initial treatment in patients with CTO
and well-developed collateral circulation. A large-
scale randomized trial is needed to conﬁrm these
ﬁndings.
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